CRSP
Price
$41.10
Change
-$3.53 (-7.91%)
Updated
Dec 18, 04:59 PM (EDT)
62 days until earnings call
LQDA
Price
$10.70
Change
-$0.61 (-5.39%)
Updated
Dec 18, 04:59 PM (EDT)
85 days until earnings call
Ad is loading...

CRSP vs LQDA

Header iconCRSP vs LQDA Comparison
Open Charts CRSP vs LQDABanner chart's image
CRISPR Therapeutics AG
Price$41.10
Change-$3.53 (-7.91%)
Volume$44.32K
CapitalizationN/A
Liquidia
Price$10.70
Change-$0.61 (-5.39%)
Volume$18.79K
CapitalizationN/A
CRSP vs LQDA Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. LQDA commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and LQDA is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (CRSP: $44.63 vs. LQDA: $11.31)
Brand notoriety: CRSP and LQDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 80% vs. LQDA: 49%
Market capitalization -- CRSP: $3.81B vs. LQDA: $957.24M
CRSP [@Biotechnology] is valued at $3.81B. LQDA’s [@Biotechnology] market capitalization is $957.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileLQDA’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • LQDA’s FA Score: 0 green, 5 red.
According to our system of comparison, LQDA is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 3 TA indicator(s) are bullish while LQDA’s TA Score has 6 bullish TA indicator(s).

  • CRSP’s TA Score: 3 bullish, 7 bearish.
  • LQDA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LQDA is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а -8.32% price change this week, while LQDA (@Biotechnology) price change was +5.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 18, 2025.

LQDA is expected to report earnings on Mar 13, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($3.81B) has a higher market cap than LQDA($906M). LQDA YTD gains are higher at: -5.985 vs. CRSP (-28.706). LQDA has higher annual earnings (EBITDA): -107.21M vs. CRSP (-313.08M). CRSP has more cash in the bank: 1.94B vs. LQDA (204M). LQDA has less debt than CRSP: LQDA (2.69M) vs CRSP (228M). CRSP has higher revenues than LQDA: CRSP (200M) vs LQDA (15.6M).
CRSPLQDACRSP / LQDA
Capitalization3.81B906M420%
EBITDA-313.08M-107.21M292%
Gain YTD-28.706-5.985480%
P/E RatioN/AN/A-
Revenue200M15.6M1,282%
Total Cash1.94B204M949%
Total Debt228M2.69M8,473%
FUNDAMENTALS RATINGS
CRSP vs LQDA: Fundamental Ratings
CRSP
LQDA
OUTLOOK RATING
1..100
6815
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
9398
PRICE GROWTH RATING
1..100
8144
P/E GROWTH RATING
1..100
83100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (63) in the Biotechnology industry is in the same range as LQDA (68) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to LQDA’s over the last 12 months.

LQDA's Profit vs Risk Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRSP (100) in the Biotechnology industry. This means that LQDA’s stock grew somewhat faster than CRSP’s over the last 12 months.

CRSP's SMR Rating (93) in the Biotechnology industry is in the same range as LQDA (98) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to LQDA’s over the last 12 months.

LQDA's Price Growth Rating (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRSP (81) in the Biotechnology industry. This means that LQDA’s stock grew somewhat faster than CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (83) in the Biotechnology industry is in the same range as LQDA (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to LQDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPLQDA
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MTCCX54.80N/A
N/A
MFS Technology C
STPCX11.99-0.04
-0.33%
Saratoga Technology & Comm C
PGOYX77.82-0.27
-0.35%
Putnam Large Cap Growth Y
ECFVX19.57-0.14
-0.71%
Eaton Vance Focused Value Opps C
REBYX30.02-0.33
-1.09%
Russell Inv US Small Cap Equity Y

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+0.88%
BEAM - CRSP
73%
Closely correlated
-1.21%
PRME - CRSP
62%
Loosely correlated
-3.00%
NTLA - CRSP
61%
Loosely correlated
-1.87%
RXRX - CRSP
60%
Loosely correlated
-4.30%
EDIT - CRSP
59%
Loosely correlated
+2.70%
More

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with ALNY. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
+2.54%
ALNY - LQDA
37%
Loosely correlated
+1.06%
AXON - LQDA
32%
Poorly correlated
-2.09%
AVXL - LQDA
30%
Poorly correlated
+0.33%
KURA - LQDA
29%
Poorly correlated
-2.36%
CRSP - LQDA
29%
Poorly correlated
+0.88%
More